Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures

US9012618B2 · kind B2 · utility

Assignee

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US

Inventors

• Nancy Sullivan · Kensington, US
• Bimal Chakrabarti · Gaithersburg, US
• Zhi-yong Yang · Potomac, US
• Maria Grazia Pau · Leiden, NL
• Jaap Goudsmit · Amsterdam, NL
• Gary J. Nabel · Cambridge, US

Key dates

• Filing date: Jan 13, 2012
• Grant date: Apr 21, 2015
• Expiry date: Jan 13, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2840/44
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.